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Key Points
• Free light chain ratio,
M-protein concentration, and
immunosuppression predict
progression of MGUS to
lymphoid malignancies.
In 728 Swedish cases of monoclonal gammopathy of undetermined significance (MGUS),
followed up to 30 years (median, 10 years), we estimated the cumulative risk of hematologic
disorders originating from lymphoid andmyeloid lineages. UsingCox regressionmodels,
we examined associations of demographic and laboratory factors with progression and
determined the discriminatory power of 3 predictionmodels for progression. Eighty-four
MGUS cases developed a lymphoid disorder, representing a cumulative risk of 15.4%.
Multiple myeloma (MM) occurred in 53 patients, and the 30-year cumulative risk was
10.6%; an ∼0.5% annual risk. Three factors were significantly associated with progression:
abnormal free light-chain (FLC) ratio (<0.26 or >1.65), M-protein concentration (‡1.5 g/dL), and reduction of 1 or 2 noninvolved
immunoglobulin isotype levels (immunoparesis). Apredictionmodelwith separate effects for these 3 factors and theM-protein isotypehad
higher discriminatory power than other models, although the differences were not statistically significant. The 30-year cumulative risk for
myeloid malignancies was <2%. Our study confirms that abnormal FLC ratio and M-protein concentration >1.5 g/dL, factors previously
consideredbyMayoClinic researchers, arepredictors forMMprogressionandsuggests that separateconsiderationof immunoparesisand
the Mayo Clinic risk factors could improve identification of MGUS patients at high risk for progression. (Blood. 2014;123(3):338-345)
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Introduction
Monoclonal gammopathies are disorders characterized by a homoge-
neous immunoglobulin (the M-protein) spike in serum or urine arising
from the proliferation of an abnormal clone of a single plasma cell
precursor. Multiple myeloma (MM) is the archetype of a malignant
monoclonal plasma cell disorder. Benign monoclonal gammopathies,
as ﬁrst described by Waldenstro¨m, also occur and are much more
common than MM.1 Once it was observed that a substantial
proportion of benign gammopathies develop into MM, the now
universally accepted term monoclonal gammopathy of undetermined
signiﬁcance (MGUS) was introduced to describe the disorder.2
In 2003, the International Myeloma Working Group (IMWG)
deﬁned diagnostic criteria differentiating MGUS from MM,
Waldenstro¨m’s macroglobulinemia (WM), and other non-Hodgkin
lymphomas (NHLs), based on the type of M-protein, its concentra-
tion, degree of bone marrow inﬁltration of plasma cells or lym-
phoplasmacytic cells, and presence of certain clinical manifestations
(the CRAB criteria).3 The term smoldering MM (SMM) was intro-
duced to distinguish a more advanced premalignant stage with
a higher risk of progression but still not requiring treatment.4
There are 3 types of MGUS with distinct natural histories: non-
IgM-(IgG or IgA)-MGUS, IgM-MGUS, and light-chain-MGUS.5,6
Although IgG and IgA- and light-chain-MGUS typically progress to
MM or develop light chain amyloidosis, IgM-MGUS cases more
often progress to WM or other NHLs.
Data from the Mayo Clinic suggest that MGUS is present in
;3% of the general white population $50 years of age and is
predominantly incidentally diagnosed.7,8 Although 2 independent
studies indicate that MGUS always precedes MM,9,10 the majority
ofMGUS patients do not progress to a lymphoproliferative disorder.
The average risk of progression is estimated to be 1%/yr, and the
25-year cumulative risk is 30%.11,12 However, there is considerable
variation in the risk of progression, and differentiating low-risk
patients, who may not need further follow-up, from high-risk patients,
who may warrant close monitoring or enrolment in early intervention
studies, is a challenge.
Several models have been published for risk stratiﬁcation of
MGUS patients.12,13 Risk factors included in a Mayo Clinic model
are non-IgG isotype, M-protein concentration $1.5 g/dL, and an
abnormal serum free light chain (FLC) ratio (normal reference:
0.26-1.65).12 Risk factors in the Spanish study group (Programa
para el Estudio de la Terape´utica en Hemopat´ıa Maligna [PETHEMA])
model are based on multiparametric ﬂow cytometry and include the
presence of .95% abnormal plasma cells and aneuploidy.13 Although
a small study of 165 MGUS patients followed for 5 years found that
3 of 5 patients who progressed to MM or WM had an abnormal
FLC ratio and 2 had an M-protein concentration $1.5 g/dL,14
no published risk model of progression has been independently
validated with a large number of MGUS cases with long-term
follow-up. We therefore assessed established risk factors and explored
novel risk factors for progression using a large independent cohort
of 728 MGUS patients followed up to 30 years.
Patients and methods
Study subjects
During the study period 1963 to 2000, there were 1202 individuals diagnosed
with MGUS at Malmo¨ University Hospital (97.8%) or another local hospital
(2.2%). The study was approved by the research ethical committee of the
University of Lund (Dnr 2009/400), and informed consent was obtained in
accordance with the Declaration of Helsinki. Per institutional procedures, for
each patient with a newly detected M-protein, 1 tube of serum was stored at
the Department of Clinical Chemistry at 220°C. However, at the time of
analysis, stored samples were no longer available for all subjects, as some
were lost or had evaporated. After visual inspection of the serum samples, we
identiﬁed 797 MGUS patients (66%) with samples of sufﬁcient quality to be
considered for analysis: 780 patients lived in Malmo¨ and 17 in neighboring
towns. We reviewed the medical records of the ﬁrst 476 patients identiﬁed
and conﬁrmed the MGUS diagnosis in 466 (97.9%). The 10 unconﬁrmed
cases were excluded. MGUS diagnosis was made according to IMWG
criteria3: M-protein concentration ,3 g/dL, absence of CRAB criteria or
clinical signs of other lymphoproliferative disorders, and,10% plasma cells
if bone marrow examination was performed. Bone marrow examination
was performed in 20% of patients with low M-protein levels, for whom
examination was not mandatory.We thus further excluded 8 individuals with
M-protein concentrations $3 g/dL ($1.5 g/dL). Of the remaining 779
MGUS patients, we excluded 35 (4.5%) subjects with missing date of birth
and/or missing date of M-protein diagnosis, 8 (1%) subjects with missing
M-protein isotype information, and 8 (1%) subjects who had a lymphoprolifer-
ative disorder prior to the date of M-protein detection, leaving a ﬁnal study
sample of 728 MGUS cases (supplemental Table 1 on the Blood Web site).
Patient characteristics and sedimentation rate were obtained from medical
records. All remaining laboratory measurements were based on analyses of
stored serum samples as described below. As a quality control step, we
investigated differences in demographic characteristics of registered MGUS
patients by inclusion status. Although there were no signiﬁcant differences in
age or gender, patients who were excluded due to serum sample availability
tended to be more recently diagnosed (median year of diagnosis 1993 vs 1986,
P , .01).
Laboratory analyses
Freelite serum free k assays (LK016.10H; Binding Site) and serum free l
assays (LK 018.10H; Binding Site) were conducted on a Roche Hitachi
Modular P turbidimeter using the manufacturer’s instructions. Using the
turbidimeter and Roche immunodiagnostic kits, we measured IgG:
03507378190, IgA: 03507246190, IgM: 03507041190, C-reactive protein:
03002039122, b2 microglobulin: 11660551216, creatinine: 11875418216,
albumin: 11970909216, and total protein: 11929917216. Electrophoresis
was performed on an InterlabMicrogel analyzer (product code SRE 601K) in
the Clinical Immunology Service, a clinical pathology accreditation–accredited
laboratory in the University of Birmingham. Nearly 20% of this study’s
stored serum samples were.30 years old. However, in analyses comparing
the concentration of protein assays, we did not ﬁnd any evidence that the
quality of samples varied by calendar year (data not shown).
Outcome ascertainment
MGUS cases with available serum samples were followed through June 1,
2009 for progression to a primary lymphoid disorder, primary myeloid
disorder, or death.We obtained the date of diagnosis of incident cancers from
3 sources: the nationwide Swedish Cancer Registry, the nationwide Patient
Registry, and the Patient Registry ofMalmo¨ University Hospital. Since 1958,
all physicians and pathologists/cytologists in Sweden are obligated by law to
report each incident case of cancer that they diagnose and/or treat to the
centralized nationwide Swedish Cancer Registry. The registry contains in-
formation on diagnosis, gender, date of birth, date of diagnosis, region/
hospital where the diagnosis was made, and data from the Swedish Cause of
Death Registry.15 In a recent validation study focusing on lymphoprolifer-
ative hematologic tumors diagnosed between 1964 and 2003, we found the
completeness and the diagnostic accuracy of the registry to be .90% to
95%.16 As light chain (AL) amyloidosis is not reported to the Swedish Cancer
Registry, information on AL amyloidosis was obtained from the Swedish
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Patient Registry, which contains all information on discharge diagnoses and
discharge listing from inpatient care since 1964 and has high coverage.17
Hematologic malignancies considered in this study and their disease
classiﬁcation codes were as follows: MM (ICD7 203.0), amyloidosis (289.2),
acute myeloid leukemia (AML) (205-206, 207.0-207.3), NHL (200.1-9,
202.1-202.9, 204.1), chronic lymphocytic leukemia (CLL) (204.1), WM
(200.3), acute lymphoblastic leukemia (ALL) (204), chronic myelogenous
leukemia (CML) (205.1), Hodgkin lymphoma (HL) (201), myeloproliferative
neoplasms (MPNs) (207.9, 208, 209), andmyelodysplastic syndromes (ICD10
D460-464, D467, D469). We further grouped hematologic disorders into 2
categories: lymphoid disorders (MM, amyloidosis, NHL, HL, and ALL) and
myeloid malignancies (AML, CML, MPNs, and myelodysplastic syndrome).
Statistical analysis
Descriptive statistics were used to summarize the sample and disease out-
comes, stratiﬁed by MGUS subtype. All event summaries refer to the ﬁrst
hematologic malignancy. Crude incidence rates were calculated as the number
of events divided by the total number of person-years at-risk following MGUS
diagnosis, and 95% conﬁdence intervals (CIs) were based on a Poisson dis-
tribution. One patient was diagnosed with NHL and amyloidosis on the same
day. For this patient, we included both events in the cause-speciﬁc analyses but
counted 1 event for analyses of the composite lymphoid outcome.
We estimated unadjusted (crude) cumulative risk,18 deﬁned as the prob-
ability of disease within a speciﬁc number of years following MGUS
diagnosis, and its 95% CI over a 30-year time period for each lym-
phoproliferative disease outcome.
Using Cox proportional hazards models, we examined the hazard ratio
associations (HRs) with progression for selected demographic and laboratory
measures and 3 risk factors previously identiﬁed by researchers at the Mayo
Clinic12 (Mayo 3): FLC ratio ,0.26 or .1.65, non-IgG subtype, and serum
M-protein $1.5 g/dL. We also assessed immunoparesis, a depression of
immunoglobulin protein levels for the noninvolved isotype, because it has
been previously implicated in the risk of progression.13 We deﬁned immuno-
paresis separately for each MGUS subtype. For subtype IgG, we considered
serum IgA ,0.88 g/L or IgM ,0.27 g/L as indicative of immunoparesis; for
subtype IgA, IgM ,0.27 g/L or IgG ,6.7 g/L; and for subtype IgM,
IgA ,0.88 g/L or IgG ,6.7 g/L.
The time scale for the Cox proportional hazards models was days from
MGUS diagnosis, and all models were adjusted for age (continuous) and year
of diagnosis (,1991,$1991), to account for the period effect we found with
serum sample availability. Observations with missing values were removed,
and we assessed the impact of their omission in sensitivity analyses that
reﬁtted themodels with a separate risk factor category for missing values.We
tested the proportional hazards assumption using Schoenfeld residuals19 and
examined the presence of age-covariate interactions by reﬁtting the Cox
models using age as the time scale.
We contrasted the discriminatory power of 3 different prediction models
for progression. The risk factors included in the different models were (1) the
count of a patient’s total number of Mayo Clinic factors (maximum of 3),
(2) the count of a patient’s total number of risk factors including immu-
noparesis and the 3 Mayo Clinic factors, and (3) individual effects for im-
munoparesis and each of the 3 Mayo Clinic factors. The last model addresses
the question of whether information about a patient’s speciﬁc combination of
risk factors, not merely the total count, improves prediction of progression.
Discriminatory ability was measured with the area under the receiver
operating characteristic curve (AUC), which represents the probability that
a model correctly assigns a higher risk to a randomly selected true case vs
a randomly selected non-case. A threefold Monte Carlo cross-validation was
used to estimate the AUC for each model, with one-third of the sample used
as the test set in each iteration of the procedure.20 Cases were deﬁned as
persons progressing within 5 years of MGUS diagnosis. To protect against
bias due to competing death, non-cases were deﬁned as persons having no
event and a minimum of 5 years of follow-up. Our procedure consisted of 50
iterations of the threefold cross-validation. We used Monte Carlo summaries
of the resulting 150 AUC estimates to obtain the mean and 95% CIs of each
model’s discriminatory ability.
Results
The 728 patients in the study cohort were diagnosed with MGUS at
a median age of 74 years (range, 28-98 years), and 21%, 46%, and
33% were diagnosed in 1963 to 1980, 1981 to 1990, and 1991 to
2000, respectively (Table 1). The most frequent MGUS subtype
was IgG with 501 patients (69%). There were 107 patients with
IgA (15%), 118 with IgM (16%), and 2 with IgE subtype (0.3%).
Twenty-four percent of the samples had evidence of immunopa-
resis (Table 1). The FLC ratio was abnormal in 47% of the patients,
and the M-protein concentration was $1.5 g/dL in 13% (median,
0.7 g/dL, range, 0.1-3.0 g/dL).
During 7590 person-years of follow-up (median, 10 years per
subject), we observed 84 lymphoid and 10 myeloid malignancies in
the study cohort (Table 2). As expected, the most frequent lymphoid
malignancy was MM (53 events), which occurred at a rate of 6.7 per
1000 person-years. Of the 10myeloidmalignancies, 7 were AML and
3 were myelodysplastic syndrome (MDS), corresponding to inci-
dence rates of 0.9 and 0.4 per 1000 person-years, respectively.
Although lymphoid and myeloid malignancy incidence rates were
similar for the IgG and IgA subtypes, no MM cases occurred
amongMGUS patients of the IgM isotype, but more than half of the
cases of NHL (59%) were among these patients, WM being the
most common NHL subtype (14/17; 82%). We observed only 3
cases of AL amyloidosis. No events of HL or ALL were observed.
There were 411 (56%) of the MGUS patients who died during
follow-up, a rate of 51 per 1000 person-years (Table 2). The median
age at death was 82 years. During up to 30 years of follow-up after
MGUS diagnosis, the cumulative risk of a lymphoid disorder was
15.4% (Figure 1A), and the cumulative risk for MM was 10.6%, an
;0.5% annual risk (Figure 1B). The cumulative risk for any lym-
phoid malignancy was steepest in the ﬁrst 10 years following
diagnosis, showing a 8.9% cumulative risk increase between 0 and
10 years and a 3.3% absolute increase in risk between 20 and 30
years (Figure 1A). A similar but less pronounced pattern was
observed for the cumulative risk for MM, with a 5.6% and 2.9%
absolute risk increase for the ﬁrst and last 10 years of observation,
respectively (Figure 1B). However, for patients diagnosed with
MGUS before age 65, the cumulative risk for progression to any
lymphoid disorder was closer to linear (supplemental Figure 1).
During up to 30 years of follow-up after MGUS diagnosis, the
cumulative risk for any myeloid malignancy was,2% (Figure 1A).
Table 3 shows the adjusted HRs for selected clinical variables in
relation to risk of hematologic malignancies. No evidence of vio-
lation of the proportionality assumption for any Cox regression
model in Table 3 was found. Immunoparesis, M-protein concentra-
tion, and abnormal FLC ratio were signiﬁcantly associated with
progression to any lymphoid event and progression to MM speci-
ﬁcally. Although the evidence was weaker, there was some sugges-
tion that high levels of b2-microglobulin were associated with higher
risk, whereas having high levels of C-reactive protein ($25 mg/L)
was associated with a lower risk of progression to a lymphoid
malignancy. None of the clinical variables we investigated were
signiﬁcantly associated with progression to a myeloid malignancy.
Of the 172 subjects with immunoparesis in the study cohort,
48 (28%) had depression of both noninvolved isotypes. To address
whether there was a dose effect for immunoparesis, we split indi-
viduals into those with no depression of a noninvolved isotype,
a depression of only 1 noninvolved isotype, and those with de-
pression of both noninvolved isotypes. For progression to any
340 TURESSON et al BLOOD, 16 JANUARY 2014 x VOLUME 123, NUMBER 3
lymphoid disorder, the HR association with depression of 1 non-
involved isotype was HR 5 2.79 (95% CI 5 1.73, 4.52), and for
immunoparesis involving 2 isotypes, HR 5 2.82 (95% CI 5 1.45,
5.46), indicating no dose effect.
We conducted several additional analyses to evaluate the robust-
ness of our ﬁndings. When we included missing data as a separate
variable category, we found similar HR associations for all studied
risk factors as for the complete-case analysis. We also obtained
similar associations when the time scale for the Cox models was age
rather than time from MGUS diagnosis.
Our ﬁndings in Table 3 suggest that immunoparesis and theMayo
Clinic 3 factors may be useful in identifying MGUS patients at higher




OverallIgG IgA IgM IgE
N 501 68.8 107 14.7 118 16.2 2 0.0 728 100.0
Follow-up, years, median (SD) 10.7 (7.7) 12.9 (7.0) 10.0 (9.2) 3.7 (2.1) 10.9 (7.8)
Gender
Male 251 50.1 51 47.7 60 50.8 2 100.0 364 50.0
Female 250 49.9 56 52.3 58 49.2 0 0.0 364 50.0
Year diagnosed
1963-1980 104 20.8 19 17.8 30 25.4 1 50.0 154 21.2
1981-1990 231 46.1 43 40.2 58 49.2 1 50.0 333 45.7
1991-2000 166 33.1 45 42.1 30 25.4 0 0.0 241 33.1
Age at diagnosis, years
25-60 92 18.4 9 8.4 15 12.7 0 0.0 116 15.9
61-70 118 23.6 24 22.4 33 28.0 1 50.0 176 24.2
71-80 177 35.3 44 41.1 39 33.1 0 0.0 260 35.7
81-90 103 20.6 27 25.2 27 22.9 1 50.0 158 21.7
91-100 11 2.2 3 2.8 4 3.4 0 0.0 18 2.5
Median age (range) 73 (28-96) 74 (53-93) 75 (38-98) 74 (67-81) 74 (28-98)
Albumin, g/L
,35 115 23.0 19 17.8 31 26.3 0 0.0 165 22.7
$35 212 42.3 41 38.3 56 47.5 2 100.0 311 42.7
Missing 174 34.7 47 43.9 31 26.3 0 0.0 252 34.6
Sedimentation rate, mm/h
0.1-40 105 21.0 18 16.8 0 0.0 1 50.0 124 17.0
41-100 118 23.6 24 22.4 0 0.0 0 0.0 142 19.5
$101 19 3.8 3 2.8 0 0.0 0 0.0 22 3.0
Missing 259 51.7 62 57.9 118 100.0 1 50.0 440 60.4
Creatinine, mmol/L
0.1-50 48 9.6 11 10.3 13 11.0 0 0.0 72 9.9
51-100 222 44.3 50 46.7 66 55.9 2 100.0 340 46.7
$101 146 29.1 35 32.7 39 33.1 0 0.0 220 30.2
Missing 85 17.0 11 10.3 0 0.0 0 0.0 96 13.2
C-reactive protein, mg/L
0.1-5 226 45.1 58 54.2 54 45.8 1 50.0 339 46.6
5-24 132 26.3 24 22.4 37 31.4 1 50.0 194 26.6
$25 138 27.5 25 23.4 27 22.9 0 0.0 190 26.1
Missing 5 1.0 0 0.0 0 0.0 0 0.0 5 0.7
b-2 microglobulin, mg/L
,3.5 313 62.5 72 67.3 78 66.1 0 0.0 463 63.6
3.5-5.5 118 23.6 22 20.6 23 19.5 2 100.0 165 22.7
.5.5 64 12.8 13 12.1 17 14.4 0 0.0 94 12.9
Missing 6 1.2 0 0.0 0 0.0 0 0.0 6 0.8
FLC ratio
0.26-1.65 267 53.3 50 46.7 66 55.9 0 0.0 383 52.6
,0.26 or .1.65 228 45.5 57 53.3 52 44.1 2 100.0 339 46.6
Missing 6 1.2 0 0.0 0 0.0 0 0.0 6 0.8
M-protein concentration, g/dL
Median, (SD) 0.7 (0.6) 0.8 (0.5) 0.7 (0.6) 0.2 — 0.7 (0.6)
,1.5 436 87.0 94 87.9 103 87.3 1 50.0 634 87.1
$1.5 63 12.6 13 12.1 15 12.7 0 0.0 91 12.5
Missing 2 0.4 0 0.0 0 0.0 1 50.0 3 0.4
Immunoparesis*
No 394 78.6 69 64.5 86 72.9 2 100.0 551 75.7
Yes 102 20.4 38 35.5 32 27.1 0 0.0 172 23.6
Missing 5 1.0 0 0.0 0 0.0 0 0.0 5 0.7
*Subtype IgG: IgA ,0.88 g/L or IgM ,0.27 g/L; subtype IgA: IgM ,0.27 g/L or IgG ,6.7 g/L; subtype IgM: IgA ,0.88 g/L or IgG ,6.7 g/L.
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risk of progressing to a lymphoid malignancy. Figure 2 shows crude
cumulative risk curves by the subgroups deﬁned by the total count of
immunoparesis and the Mayo Clinic 3 risk factors. This plot suggests
an increasing risk with the number of factors, with a striking dif-
ference in the risk curves between patients with $3 risk factors
compared with those with#2, although we did not have sufﬁcient
follow-up data to estimate risk beyond 10 years for individuals
with all 4 risk factors. Within the ﬁrst 10 years, the addition of 1
risk factor for persons with $1 risk factor approximately doubled
the cumulative risk of progression (Figure 2).
To formally assess the comparative performance of risk factors for
prediction of progression, we compared the cross-validated AUCs of
risk models with (1) the total count among the 3 Mayo Clinic factors,
(2) the total count of immunoparesis and the 3 Mayo Clinic factors,
and (3) a multivariable model with separate effects for immunoparesis
and the 3Mayo Clinic factors. Themultivariable model best predicted
the risk of a lymphoid disorder (cross-validated AUC 5 0.73, 95%
CI 5 0.59, 0.85; supplemental Figure 2A) and MM speciﬁcally
(cross-validated AUC 5 0.81, 95% CI 5 0.67, 0.94; supplemental
Figure 2B). However, this AUC was not statistically signiﬁcantly
higher than the AUC of a model with the count of the 3 Mayo Clinic
factors (cross-validated AUC [lymphoid malignancy] 5 0.71, 95%
CI 5 0.58, 0.85; and cross-validated AUC [myeloid malignancy] 5
0.74, 95% CI 5 0.54, 0.89).
Table 2. Summary of lymphoid and myeloid outcomes and incidence rates (per 1000 person-years)
Outcome
Ig isotype*
All Ig isotypes combinedIgG IgA IgM
Events Rate (95% CI)
Median
age
(years)† Events Rate (95% CI)
Median
age
(years)† Events Rate (95% CI)
Median
age




Lymphoid 54‡ 10.3 (7.7, 13.4) 78 13 10.7 (5.7, 18.3) 71 17 14.6 (8.5, 23.3) 79 84c 11.0 (8.8, 13.6) 76
MM 42 7.9 (5.7, 10.6) 77 11 8.8 (4.4, 15.8) 72 0 0.0 (0.0, 2.8) 53 6.7 (5.0, 8.8) 75
Amyloidosis 2 0.4 (0.0, 1.3) 71 1 0.8 (0.0, 4.3) 71 0 0.0 (0.0, 2.8) 3 0.4 (0.1, 1.1) 71
NHL 11 2.0 (1.0, 3.6) 78 1 0.8 (0.0, 4.3) 60 17 14.6 (8.5, 23.3) 79 29 3.7 (2.5, 5.3) 78
CLL 1 0.2 (0.0, 1.0) 49 0 0.0 (0.0, 2.8) 3 2.3 (0.5, 6.7) 75 1 0.1 (0.0, 0.7) 49
Waldenstro¨m 0 0.0 (0.0, 0.7) 0 0.0 (0.0, 2.8) 14 11.7 (6.4, 19.6) 79 3 0.4 (0.1, 1.1) 75
Other 10 1.8 (0.9, 3.4) 78 1 0.8 (0.0, 4.3) 60 0 0.0 (0.0, 2.8) 25 3.2 (2.0, 4.7) 79
Hodgkin 0 0.0 (0.0, 0.7) 0 0.0 (0.0, 2.8) 0 0.0 (0.0, 2.8) 0 0.0 (0.0, 0.4) 0
ALL 1 0.2 (1.0, 3.6) 49 0 0.0 (0.0, 2.8) 0 0.0 (0.0, 2.8) 1 0.1 (0.0, 0.7) 49
Myeloid 8 1.4 (0.6, 2.9) 81 1 0.8 (0.0, 2.8) 90 1 0.8 (0.0, 4.3) 64 10 1.2 (0.6, 2.3) 81
AML 5 0.9 (0.3, 2.1) 79 1 0.8 (0.0, 2.8) 90 1 0.8 (0.0, 4.3) 64 7 0.9 (0.3, 1.8) 79
CML 0 0.0 (0.0, 0.7) 0 0.0 (0.0, 2.8) 0 0 0.0 (0.0, 2.8) 0 0.0 (0.0, 0.4)
MDS 3 0.5 (0.1, 1.6) 83 0 0.0 (0.0, 2.8) 0 0 0.0 (0.0, 2.8) 3 0.4 (0.1, 1.1) 83
MPD 0 0.0 (0.0, 0.7) 0 0.0 (0.0, 2.8) 0 0 0.0 (0.0, 2.8) 0 0.0 (0.0, 0.4)
Mortality 291 52.8 (46.9, 59.2) 84 55 42.6 (32.1, 55.5) 84 63 48.5 (37.3, 62.1) 82 411 50.7 (45.9, 55.8) 82
MPD, myeloproliferative disorders.
*Summaries for the 2 patients with MGUS subtype E have been omitted, as neither experienced a lymphoproliferative event.
†Age of cases at disease diagnosis or death.
‡Total is not the sum of the subtypes because 2 persons had diagnoses on the same date. One person was diagnosed with NHL and amyloidosis on the same date and another
person with NHL and ALL on the same date. Both diagnoses are included in the NHL and amyloidosis counts but are counted as 1 event for the composite lymphoid outcome.
Figure 1. Cumulative risk of a lymphoproliferative event in years from MGUS diagnosis. (A) Cumulative risk for the grouped outcomes of lymphoid (MM, amyloidosis,
NHL, Hodgkin lymphoma, ALL) and myeloid (AML, CML, MDS, myeloproliferative disorder) events. (B) Event-specific cumulative risk for MM, NHL, and AML. Bars denote the
95% CI.
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Discussion
In this study of 728 MGUS cases followed up to 30 years, we
estimated the risk of lymphoid disorders and myeloid malignancies.
We assessed established risk factors and explored novel factors
for progression. Based on 84 patients who progressed to a
lymphoid disorder, the 30-year cumulative risk was 15.4%
overall and 10.6% for MM. The absolute risk of progression to
any lymphoid disorder or MM speciﬁcally increased most
steeply during the ﬁrst 10 years following MGUS diagnosis.
Consistent with earlier reports,21,22 cause-speciﬁc risks among
lymphoid disorders highly depended on M-protein isotype. No
MM cases occurred among patients diagnosed with IgM MGUS,
whereas the rate of NHL was much higher in patients with IgM
MGUS compared with the IgG or IgA subtypes (14.6 vs 2.0 and
0.8 per 1000 person-years). Also as previously observed,6
progression to any myeloid malignancy was comparatively infre-
quent, having a 30-year cumulative risk ,2%.
We found 3 clinical variables to be signiﬁcantly associated with
progression to any lymphoid malignancy or MM: M-protein concen-
tration $1.5 g/dL, abnormal FLC ratio, and presence of immunopa-
resis. In 2002, in a long-term study of prognosis in MGUS patients at
the Mayo Clinic, the size of the M-protein at the time of MGUS
diagnosis was the most important predictor of progression, and this
observation has been conﬁrmed in several studies.11 The negative
impact of an abnormal FLC ratio was ﬁrst reported in 2005,12 and the
present study is the ﬁrst to conﬁrm the role of an abnormal FLC ratio in
a large independent cohort of MGUS patients with long-term follow-
up. Regarding immunoparesis, conﬂicting ﬁndings have been re-
ported. In the Mayo Clinic series, the concentration of uninvolved
immunoglobulins was reduced in 38% of patients but was not
predictive of progression to MM. In the Spanish PETHEMA series,
immunoparesis was signiﬁcantly associated with progression to MM
among both MGUS and SMM patients when assessed in univariate
analyses; however, in a multivariate analysis, a signiﬁcant association
remained only in SMM.13
In contrast to previous reports,11,12,23 we did not observe a
difference in the risk of progression in non-IgG vs IgG MGUS. No
association was found between M-protein isotype and risk of pro-
gression in the PETHEMA study.13 The reason for these differ-
ences is not clear. The interpretation of the association of isotype
with progression is complicated by the different types of lymphoid
malignancies in IgM vs IgG/IgA MGUS. Also, due to the higher
catabolic rate of IgA and IgM compared with IgG,24 at a given
M-protein concentration in serum, there is on the average more
clonal cells in MGUS of these isotypes than in IgG-MGUS.
A model that considered the separate effects of eachMayo Clinic
risk factor (FLC ratio, M-protein concentration, and isotype) and
immunoparesis better predicted the risk of progression than a model
using only the count of present factors, although the difference was
not statistically signiﬁcant. This ﬁnding suggests that a patient’s
particular combination of risk factors could improve the prediction
of his or her risk of progression. On a clinical note, in our study,
patients with all 4 risk factors had a very high rate (40%) of
progression within 10 years and constitute a group who should be
followed carefully and recommended for interventional studies.
A small group of patients with a high rate of progression (46% after
5 years) was also identiﬁed in the model proposed by the Spanish
PETHEMA group.13
Strengths of our study were the large sample size and 30 years
of follow-up. However, the use of retrospective data collection
from medical records and case ascertainment from a national cancer
registry had several limitations. There were 390 patients (after
excluding 15 SMM cases) who did not have adequate serum
samples to be included in the risk factor analyses. Although their




HR P value HR P value HR P value
Albumin
,35 1.00 1.00 1.00
$35 1.50 .240 1.40 .430 1.30 .808
Sedimentation rate
0.1-40 1.00 1.00 1.00
41-100 1.12 1.15 0.92
$101 0.89 .916 0.99 .927 ,0.01 .805
C-reactive protein
0.1-5 1.00 1.00 1.00
5-24 1.50 1.12 0.35
$25 0.60 .024 0.33 .038 1.03 .526
b-2 microglobulin, mg/L
,3.5 1.00 1.00 1.00
3.5-5.5 1.57 1.27 0.40
.5.5 2.06 .082 1.77 .474 1.41 .521
Immunoparesis*
No 1.00 1.00 1.00
Yes 2.80 ,.001 2.77 ,.001 1.00 .996
Mayo Clinic model
FLC ratio
0.26-1.65 1.00 1.00 1.00
,0.26 or .1.65 2.32 ,.001 3.03 ,.001 0.60 .468
M-protein, g/dL
,1.5 1.00 1.00 1.00
$1.5 3.68 ,.001 3.64 ,.001 0.80 .823
Isotype
IgG 1.00 1.00 1.00
non-IgG 1.19 .458 0.54 .055 0.49 .336
Proportional hazards models were adjusted for age and year at diagnosis.
*Isotype IgG: IgA ,0.88 g/L or IgM ,0.27 g/L; isotype IgA: IgM ,0.27 g/L or
IgG ,6.7 g/L; isotype IgM: IgA ,0.88 g/L or IgG ,6.7 g/L.
Figure 2. Cumulative risk of a lymphoid event in years from MGUS diag-
nosis stratified by the count of total risk factors among the Mayo 3 and
immunoparesis factors. Bars denote the 95% CI.
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exclusion reduced our study’s power (which was especially limited
for the study of myeloid malignancies), we do not believe it
introduced a selection bias because sample availability was not
associated with patient demographics, and there was no difference in
the risk of progression between excluded and included patients (age-
adjusted lymphoproliferative disease HR 5 0.91, 95% CI 5 0.64,
1.29). We attempted to collect information on several additional
variables (haptoglobin, hemoglobin, and white blood cell count),
but the information available from medical records was too in-
complete to be analyzed. Other risk factors based on ﬂow cytom-
etry13 and genetic factors25 were also not available for analysis.
Moreover, because bone marrow examination was not performed
in a large proportion of patients with low M-protein concentrations,
we could not determine whether some patients in the sample would
have fulﬁlled criteria for SMM. Neither could we exclude light-
chain MGUS cases, as serum FLC assays were not available during
the study period. Also, the reported incidence of AL amyloidosis is
likely underestimated, because it is based on in-patient registry data
that only includes cases needing hospitalization.
Since 1978,2 varying rates of progression to MM and other
lymphoid malignancies have been reported forMGUS patients, with
the majority of published rates being based on small patient series
and short-term follow-up.21,26,27 In a large long-term follow-up
study of 1148 MGUS patients treated at the Mayo Clinic, the 25-
year cumulative risk ofMMwas 30% (1% annual risk), a substantially
higher rate of progression than the 0.5% annual risk observed in our
study.12 Although the median age atMGUS diagnosis, MGUS isotype
distribution, and M-protein concentration were very similar for both
cohorts, the percentage ofMGUS patients with an abnormal FLC ratio
was higher in our study (47% vs 33%). However, the higher prev-
alence of abnormal FLC ratio is in contrast with the lower risk of
progression we found.
Owing to possible differences in the intensity of monitoring and
case completeness between registry- and clinically based cohorts,
the differences between progression rates in the Swedish and Mayo
Clinic cohorts (0.5% vs 1% annual risk of progression, respec-
tively) may not reﬂect true population heterogeneity but rather
differences in study design. Although the ascertainment rate of the
Swedish Cancer Registry is high,16 there could still be under-
reporting of hematologic malignancies. We therefore performed
case veriﬁcation for lymphoid disorders in the inpatient registry of
Malmo¨ University Hospital using a detailed medical record review.
Due to limited resources, only records for the ﬁrst 476 patients in
our study could be reviewed. Among these patients, we found 63
cases of a lymphoproliferative disorder during follow-up, and of
these, 3 (2 cases of MM and 1 case of WM; 4.7%) were not
reported to the Cancer Registry but were subsequently included in
our study. Based on this ﬁnding, we expect 1.5 cases of a lym-
phoproliferative disease in the Swedish cohort might have been
missed due to underreporting. Thus, underreporting cannot fully
account for the differences between the Swedish and Mayo Clinic
cohort progression rates. However, Mayo Clinic MGUS patients
may have been more intensively monitored than the Swedish cohort,
as suggested by the high prevalence of SMM reported in these
patients. It is unclear to what extent heightened surveillance could
explain the comparatively higher rate of progression reported by the
Mayo Clinic investigators.
In conclusion, in an independent, large cohort of MGUS patients
with long-term follow-up, we conﬁrmed that an abnormal FLC ratio
predicts risk for progression of MGUS. This is an important ob-
servation as serum FLC assays are commonly used in the clinical
setting while no replication of the Mayo Clinic risk model12 has
been available until date. Furthermore, our results conﬁrm the pre-
dictive value of a highM-protein concentration. A novel observation in
our study is that the addition of immunoparesis to a multivariable
model that includes independent effects for the factors of the Mayo
Clinic risk model increases the discriminatory power to identify
high-risk (vs low-risk) MGUS patients.
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